Spinraza (nusinersen) treatment may help restore balance to the levels of some lipids, fat-like molecules that are lower in the cerebrospinal fluid (CSF) of children with spinal muscular atrophy (SMA) ...

Lilly said patients must refill their prescriptions of the two higher-dose vials within 45 days of their first fill to get the same pricing, and would otherwise have to pay as much as $699 for ...

Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. A bunch of people I know (including me) have gotten sick ...

Shares of the Indianapolis-based drugmaker rose 2.3% to $902.42. The launch of Lilly's vials expands options for patients who choose to pay cash through the drugmaker's direct-to-consumer website ...

There was no treatment until Doctor Adrian Krainer with Cold Spring Harbor lab on Long Island led the way to creation of Spinraza, a first FDA-approved treatment for Spinal Muscular Atrophy.

Police allegedly found the vial after Mr Nadir and Sarah Abu Lebdeh were stood down from their roles at Bankstown Hospital following the emergence of the video, 7NEWS reported. After Mr Nadir ...

The firm expanded its neurology portfolio beyond MS, including the blockbuster Spinraza for spinal muscular atrophy, or SMA, a rare neuromuscular disease. We see Biogen as a firm in transition ...

The two other SMA stalwarts on the market, Biogen’s oligonucleotide Spinraza and Novartis’ gene therapy Zolgensma, are delivered intrathecally (into the cerebrospinal fluid around the spinal ...

Treatment with Spinraza (nusinersen), which was the first disease-modifying therapy to be approved for spinal muscular atrophy (SMA) back in 2016, does not lead to significant kidney dysfunction in ...

However while Spinraza had a very strong launch in the first half of 2017, its US sales faltered in Q3 to $197.6 million, barely above the $194.8 million achieve in the previous quarter.